Up to 37% of patients with hematological neoplasms treated with CD-19 targeted CAR T-cell therapy reported cognitive impairment in one or more cognitive domains including memory, language, attention, and executive functioning, even up to 90 days after treatment (55, 56). This evidence concerns the gene CD19 and Cognitive impairment.